Jan 2023 Novel Psychoactive Substances: What is Xylazine?
Substance use can take many forms and often involves many unknowns. One of the most important aspects of illicit substance...
Clinical Update
Dec 2022 Medication Monitoring in a Changing Opioid Prescribing Landscape
The new 2022 CDC Clinical Practice Guideline for Prescribing Opioids for Pain is an update to the most recent practice...
Nov 2022 Aegis’s Novel Psychoactive Substances Testing Menu Update
In September, Aegis updated both urine and oral fluid novel psychoactive substance (NPS) test menus as a continued commitment to...
Oct 2022 A Brief Look at QTc Prolongation, Serotonin Syndrome, and Tardive Dyskinesia
Introduction Some combinations of medications can lead to serious pharmacodynamic interactions with clinical effects that can be life-threatening in some cases....
Sep 2022 Complexities of Risk Assessment: Opioids, Drug Interactions, & Designer Benzodiazepines
As the number of fatal and non-fatal overdoses continues to rise, we should question why this is occurring. One frequent...
Aug 2022 Behavioral Health: Why Monitor Patients for Medication Adherence?
Mental health illness affects almost a half billion people globally every year including millions of Americans. Data from 2020 showed...
